{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+all-trans+retinoic+acid+%28ATRA%29", "query": { "intervention": "Oral all-trans retinoic acid (ATRA)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+all-trans+retinoic+acid+%28ATRA%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-13T06:33:49.072Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04303169", "title": "Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vibostolimab", "type": "BIOLOGICAL" }, { "name": "Gebasaxturev", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Favezelimab + Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ATRA", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 146, "start_date": "2020-06-26", "completion_date": "2025-09-24", "has_results": true, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04303169" }, { "nct_id": "NCT07504458", "title": "Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Promyelocytic Leukemia (APL)", "Acute Promyelocytic Leukaemia", "Acute Promyelocytic Leukemia With PML-RARA", "Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA", "Acute Promyelocytic Leukemia" ], "interventions": [ { "name": "QTX-2101 + ATRA", "type": "DRUG" }, { "name": "IV arsenic trioxide (ATO) + ATRA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Quetzal Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "71 Years", "sex": "ALL", "summary": "18 Years to 71 Years" }, "enrollment_count": 150, "start_date": "2026-06-08", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • Irvine, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07504458" }, { "nct_id": "NCT00413166", "title": "All-trans Retinoic Acid, and Arsenic +/- Idarubicin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Promyelocytic Leukemia" ], "interventions": [ { "name": "All-Trans Retinoic Acid (ATRA)", "type": "DRUG" }, { "name": "Arsenic Trioxide (ATO)", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 78, "start_date": "2006-12", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413166" }, { "nct_id": "NCT04700176", "title": "A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "All-trans retinoic acid", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2022-05-02", "completion_date": "2023-11-15", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04700176" }, { "nct_id": "NCT02758990", "title": "Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Rhinitis", "Rhinitis, Allergic", "Respiratory Sounds", "Dyspnea", "Headache", "Migraine Disorders", "Arthritis", "Arthralgia", "Anxiety", "Sleep Initiation and Maintenance Disorders", "Sleep Deprivation" ], "interventions": [ { "name": "Vitamin A", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin B6", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin C", "type": "DIETARY_SUPPLEMENT" }, { "name": "Nicotinamide", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin D3", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin E", "type": "DIETARY_SUPPLEMENT" }, { "name": "Broccoli", "type": "OTHER" }, { "name": "Spinach", "type": "OTHER" }, { "name": "Caffeine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Coffee", "type": "OTHER" }, { "name": "Axon Eyewear", "type": "DEVICE" }, { "name": "Chocolate", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "DEVICE" ], "sponsor": "Verifomics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2016-03", "completion_date": "2016-11-23", "has_results": false, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02758990" }, { "nct_id": "NCT04305054", "title": "Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vibostolimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab/Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Favezelimab/Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ATRA", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 335, "start_date": "2020-07-01", "completion_date": "2026-05-18", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 15, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305054" }, { "nct_id": "NCT02712905", "title": "An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors and Hematologic Malignancy" ], "interventions": [ { "name": "INCB059872", "type": "DRUG" }, { "name": "all-trans retinoic acid (ATRA)", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2016-05-05", "completion_date": "2022-04-14", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 11, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02712905" }, { "nct_id": "NCT01275274", "title": "Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis" ], "interventions": [ { "name": "Retinoic acid", "type": "DRUG" }, { "name": "Standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2012-01", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01275274" }, { "nct_id": "NCT06528769", "title": "Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leiomyosarcoma", "Sarcoma" ], "interventions": [ { "name": "all-trans retinoic acid", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Gabriel Tinoco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2025-09-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06528769" }, { "nct_id": "NCT02401295", "title": "ATRA, Celecoxib, and Itraconazole as Maintenance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Multiple Myeloma" ], "interventions": [ { "name": "ATRA", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2015-05", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-10-13T06:33:49.072Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401295" } ] }